Chronic Eosinophilic Leukemia, NOS (CEL-NOS) — Specialist Haematology & Targeted Therapy Access

Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL-NOS) is a rare type of blood cancer characterised by the persistent, abnormal overproduction of eosinophils — a type of white blood cell normally involved in fighting parasitic infections and allergic reactions. In CEL-NOS, this overproduction is clonal (arising from a single abnormal blood stem cell) and cannot be attributed to a known genetic driver (such as a specific gene rearrangement) or to a reactive cause (such as allergy or infection). The condition belongs to the group of myeloproliferative neoplasms. The main danger is that excess eosinophils can deposit in organs and cause damage — particularly to the heart, lungs, skin, and nervous system.

Both CEL-NOS and hypereosinophilic syndrome (HES) are characterised by persistent high eosinophil counts causing organ damage, and the distinction between them can be challenging. The key difference is evidence of clonality: CEL-NOS requires demonstration of a clonal abnormality — either an increase in blood or bone marrow blast cells (immature leukaemia cells), a clonal cytogenetic abnormality on bone marrow karyotyping, or a clonal somatic mutation. Idiopathic HES lacks these clonal markers. This distinction matters because CEL-NOS has a higher risk of transforming to acute leukaemia and may require more aggressive treatment, while HES is managed more like an inflammatory disorder with corticosteroids and anti-IL-5 biologics.

FIP1L1-PDGFRA is a gene rearrangement that causes a related but distinct condition — 'myeloid/lymphoid neoplasm with PDGFRA rearrangement' — that is NOT visible on routine blood tests or even on standard bone marrow karyotyping. It can only be detected by a specific FISH or RT-PCR test for this fusion gene. This matters enormously because FIP1L1-PDGFRA-positive disease responds dramatically to low-dose imatinib (a targeted tablet medication), achieving complete remission in the vast majority of patients. Missing this diagnosis and treating with standard chemotherapy would be a major clinical error. FIP1L1-PDGFRA testing is therefore mandatory before CEL-NOS can be diagnosed.

Excess eosinophils release toxic granule proteins and cytokines that damage tissues wherever they accumulate. The most serious is cardiac damage: eosinophilic endomyocarditis (Löffler's endomyocarditis) causes inflammation and then permanent fibrosis of the inner heart lining, leading to heart failure, valvular dysfunction, and intracardiac blood clots that can cause stroke. Other organs affected include the lungs (causing breathlessness and infiltrates), skin (itching, rashes, and ulcers), the nervous system (peripheral neuropathy), and the gastrointestinal tract. Cardiac monitoring with echocardiography and troponin blood tests is therefore a critical part of CEL-NOS management from diagnosis onwards.

The most commonly used first-line treatment for CEL-NOS is hydroxyurea — an oral medication that reduces eosinophil production by inhibiting cell division in bone marrow progenitors. It is titrated to the lowest effective dose that keeps eosinophil counts under control. When acute organ damage (particularly cardiac) is present, high-dose corticosteroids (prednisolone) are used alongside hydroxyurea for rapid eosinophil suppression. For patients who do not have FIP1L1-PDGFRA but fail hydroxyurea, a trial of imatinib may be considered. Mepolizumab (anti-IL-5 biologic) is another option for steroid-dependent or hydroxyurea-intolerant patients.

Yes. A minority of patients with CEL-NOS can experience blast phase transformation — where the disease evolves into an acute leukaemia (usually acute myeloid leukaemia, AML) characterised by ≥20% blast cells in the bone marrow. The risk of this transformation is one of the main reasons that serial bone marrow monitoring is part of CEL-NOS management. Patients with high-risk features — rising blast counts approaching 10–19%, complex karyotype, or adverse molecular mutations — are considered for allogeneic stem cell transplantation before blast phase transformation occurs, as outcomes after transformation are very poor. Early transplant evaluation in high-risk patients is therefore an important management priority.

Imatinib is the definitive treatment for FIP1L1-PDGFRA-positive eosinophilic neoplasm — which is a different (though related) WHO entity from CEL-NOS. In true CEL-NOS (where PDGFRA and PDGFRB rearrangements have been excluded), imatinib is not routinely effective, because CEL-NOS by definition lacks the specific kinase target. However, because some cryptic or low-level PDGFRA rearrangements may be missed by standard testing, an empirical trial of imatinib is sometimes considered in patients with CEL-NOS who fail hydroxyurea — with response assessment after 1–3 months. Response to imatinib in this context may indicate a previously undetected PDGFR driver.

Patients with CEL-NOS require regular monitoring to track disease activity, treatment response, and detect complications. Blood count and differential monitoring should occur every 4–8 weeks during active treatment; stable patients may be monitored less frequently. Cardiac monitoring — serum troponin, BNP, and echocardiography — is performed at baseline and every 3–6 months (or sooner if cardiac symptoms develop) to detect early endomyocardial damage. Bone marrow assessment is repeated when eosinophil counts escalate or symptoms worsen, or as directed by clinical response. Pulmonary function tests and skin examination are also part of the regular surveillance schedule.

Yes. CancerFax provides specialist support for patients with rare and complex myeloid malignancies like CEL-NOS. We review bone marrow biopsy and aspirate reports, FISH and RT-PCR molecular testing results (including FIP1L1-PDGFRA), karyotype findings, echocardiography and troponin data, and NGS somatic mutation profiles — then connect patients with expert haematologists and myeloproliferative neoplasm specialists in India, Germany, South Korea, the UAE, and other countries with specialist rare leukaemia and MPN programmes. We assist with second opinion coordination to confirm the CEL-NOS diagnosis and exclude imatinib-sensitive entities, guidance on hydroxyurea and mepolizumab access, allogeneic SCT evaluation, clinical trial identification, and end-to-end coordination for international specialist haematology care.